An official website of the United States government
Enable a system biology approach to decipher the complex role of the microbiome in brain aging and AD/ADRD and as a modifier of responsiveness to treatment (pharmacologic and non-pharmacologic). Robust and rigorous study of the microbiome will require that relevant biosamples, high quality molecular data, and analytical tools are made available as a community resource.
2024 RFA-AG-17-054: Enhancing the Target and Biomarker Discovery Efforts of the AMP AD and M2OVE-AD Consortia (R01) PAR-17-029: Dynamic Interactions between Systemic or Non-Neuronal Systems and the Brain in Aging and in Alzheimer’s Disease (R01) 2.I Achieved Enable a system biology approach to decipher the complex role of the microbiome in brain aging and AD/ADRD... DN 2018 AD Summit: 2J and 5D 2021 AD Summit: 7.I and 7.J Highlight: Scientists explore how skin, mouth, and gut microbiomes change with aging Highlight: Gut microbes may affect motivation to exercise Highlight: Beyond the brain: The gut microbiome and Alzheimer’s disease Highlight: Changes in human microbiome precede Alzheimer’s cognitive declines Research on Disease Mechanisms NIH Common Fund Human Microbiome Program Alzheimer’s Gut Microbiome Project Gut microbiota-based biomarkers of Alzheimer's disease and its modulation by a ketogenic diet Multi-omic Investigation of Exercise Effects in Mild Cognitive Impairment
- Support microbiome molecular profiling (metagenome, meta-transcriptome, metaproteome and metabolome) across diverse cohorts and in clinical trials to enable systems-based, data-driven approaches aimed at understanding the role of the microbiome in disease heterogeneity, gene-environment interactions, health disparities, and differential responsiveness to treatment. Ensure that these efforts mandate rapid and broad sharing of data, analytical tools and biosamples and that they leverage the resources and knowledge generated by the NIH Common Fund Human Microbiome Program.
Summary of Key Accomplishments
NIA supports research to examine the role of the microbiome in brain aging and AD/ADRD and as a modifier of responsiveness to treatment, as well as a potential therapeutic target. The NIA-funded Alzheimer’s Gut Microbiome Project (AGMP), led by an international, cross-disciplinary team of investigators, brings together researchers from the Human Microbiome Project and the larger AD/ADRD field experience in metabolomics, systems biology, basic, translational, and clinical research, including investigators from over ten AD Research Centers. Over the course of five years, the AGMP will deliver a wealth of datasets from human cohorts and animal models and rich analytical tools to share with the greater research community.
The key accomplishments summary is current as of July 2022.